Eric Ni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric Ni has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Mark Gerstein
Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT 06520, USA
4 shared publications - Gamze Gürsoy
Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, CB3 0WA, UK
3 shared publications - Timothy Cardozo
NYU Langone Health
3 shared publications - Charlotte M. Brannon
Computational Biology and Bioinformatics Program, Yale University, New Haven, USA
2 shared publications - Susanna Liu
Molecular, Cellular, and Developmental Biology, Yale University, New Haven, USA
2 shared publications - Tianxiao Li
NEC Laboratories America
2 shared publications
Latest Publications
- Open Access
- 30 March 2025
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 165, 104818
Scalable and efficient on-chain data management in blockchain for large biomedical data
- 30 March 2025
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 165, 104818
Open AccessScalable and efficient on-chain data management in blockchain for large biomedical data
- 10 May 2023
- Published by Springer Nature
- p. 79-93
Security Vulnerabilities and Countermeasures for the Biomedical Data Life Cycle
- 10 May 2023
- Published by Springer Nature
- p. 79-93
Security Vulnerabilities and Countermeasures for the Biomedical Data Life Cycle
- 22 November 2021
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 23 (4) , 259
Author Correction: Functional genomics data: privacy risk assessment and technological mitigation
- 22 November 2021
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 23 (4) , 259
Author Correction: Functional genomics data: privacy risk assessment and technological mitigation
- 10 November 2021
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 23 (4) , 245-258
Functional genomics data: privacy risk assessment and technological mitigation
The generation of functional genomics data by next-generation sequencing has increased greatly in the past decade. Broad sharing of these data is essential for research advancement but poses notable privacy challenges, some of which are analogous to those that occur when sharing genetic variant data. However, there are also unique privacy challenges that arise from cryptic information leakage during the processing and summarization of functional genomics data from raw reads to derived quantities, such as gene expression values. Here, we review these challenges and present potential solutions for mitigating privacy risks while allowing broad data dissemination and analysis.
- 10 November 2021
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 23 (4) , 245-258
Functional genomics data: privacy risk assessment and technological mitigation
The generation of functional genomics data by next-generation sequencing has increased greatly in the past decade. Broad sharing of these data is essential for research advancement but poses notable privacy challenges, some of which are analogous to those that occur when sharing genetic variant data. However, there are also unique privacy challenges that arise from cryptic information leakage during the processing and summarization of functional genomics data from raw reads to derived quantities, such as gene expression values. Here, we review these challenges and present potential solutions for mitigating privacy risks while allowing broad data dissemination and analysis.
- 11 June 2018
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 9 (7) , 1093-1104
Chemical probes of Skp2-mediated p27 ubiquitylation and degradation
Skp2 is a member of the F-box family of proteins that serve as substrate-specific adaptors in Skp1–CUL1–ROC1–F-box (SCF) E3 ubiquitin ligases. Skp2 (Fbxl1) directly binds to the tumor suppressor p27 in the context of the SCFSkp2 E3 ubiquitin ligase to ubiquitylate and target-phosphorylated p27 for proteasomal degradation. As p27 is a powerful suppressor of growth in a variety of cells, and as Skp2 is also overexpressed in many human cancers, Skp2 is considered an oncogene and an intriguing drug target. However, despite 20 years of investigation, a valid chemical inhibitor of Skp2-mediated degradation of p27 has not been identified. Recently, an increasing number of compounds designed to have this bioactivity have been reported. Here, we conduct a meta-analysis of the evidence regarding bioactivity, structure, and medicinal chemistry in order to evaluate and compare these Skp2 inhibitor compounds. Despite chemically diverse compounds with a wide array of Skp2-mediated p27 ubiquitylation inhibition properties reported by several independent groups, no current chemical probe formally qualifies as a validated pharmaceutical hit compound. This finding suggests that our knowledge of the structural biochemistry of the Skp2–p27 complex remains incomplete and highlights the need for novel modes of inquiry.
- 11 June 2018
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 9 (7) , 1093-1104
Chemical probes of Skp2-mediated p27 ubiquitylation and degradation
Skp2 is a member of the F-box family of proteins that serve as substrate-specific adaptors in Skp1–CUL1–ROC1–F-box (SCF) E3 ubiquitin ligases. Skp2 (Fbxl1) directly binds to the tumor suppressor p27 in the context of the SCFSkp2 E3 ubiquitin ligase to ubiquitylate and target-phosphorylated p27 for proteasomal degradation. As p27 is a powerful suppressor of growth in a variety of cells, and as Skp2 is also overexpressed in many human cancers, Skp2 is considered an oncogene and an intriguing drug target. However, despite 20 years of investigation, a valid chemical inhibitor of Skp2-mediated degradation of p27 has not been identified. Recently, an increasing number of compounds designed to have this bioactivity have been reported. Here, we conduct a meta-analysis of the evidence regarding bioactivity, structure, and medicinal chemistry in order to evaluate and compare these Skp2 inhibitor compounds. Despite chemically diverse compounds with a wide array of Skp2-mediated p27 ubiquitylation inhibition properties reported by several independent groups, no current chemical probe formally qualifies as a validated pharmaceutical hit compound. This finding suggests that our knowledge of the structural biochemistry of the Skp2–p27 complex remains incomplete and highlights the need for novel modes of inquiry.
- Open Access
- 1 January 2018
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 16, 350-360
Triazolo[4,5 -d ]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce Growth of Leukemia Cells
Cellular stress signals activate adaptive signaling pathways of the mammalian integrated stress response (ISR), of which the unfolded protein response (UPR) is a subset. These pathways converge at the phosporylation of eIF2α. Drug-like, potent and selective chemical inhibitors (valid chemical probes) targeting major ISR kinases have been previously identified, with the exception of GCN2. We synthesized and evaluated a series of GCN2 inhibitors based on a triazolo[4,5-d]pyrimidine scaffold. Several compounds potently inhibited GCN2 in vitro and displayed good selectivity over the related kinases PERK, HRI, and IRE1. The compounds inhibited phosporylation of eIF2α in HEK293T cells with an IC50 < 150 nM, validating them as chemical probes for cellular studies. These probes were screened against the National Cancer Institute NCI-60 human cancer cell line panel. Uniform growth inhibition was observed in the leukemia group of cell lines. Growth inhibition in the most sensitive cell lines coincided with high GCN2 mRNA expression levels. Oncomine analysis revealed high GCN2 expression accompanied by lower asparagine synthetase (ASNS) expression in patient-derived acute lymphoblastic leukemias with B-Cell origins (B-ALL) as well. Notably, asparaginase, which depletes amino acids and triggers GCN2 activity, is a licensed, first-line B-ALL treatment. Thus, we hypothesize that leukemias exhibiting high GCN2 expression and low ASNS expression may be susceptible to pharmacologic GCN2 inhibition.
- 1 January 2018
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 16, 350-360
Open AccessTriazolo[4,5 -d ]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce Growth of Leukemia Cells
Cellular stress signals activate adaptive signaling pathways of the mammalian integrated stress response (ISR), of which the unfolded protein response (UPR) is a subset. These pathways converge at the phosporylation of eIF2α. Drug-like, potent and selective chemical inhibitors (valid chemical probes) targeting major ISR kinases have been previously identified, with the exception of GCN2. We synthesized and evaluated a series of GCN2 inhibitors based on a triazolo[4,5-d]pyrimidine scaffold. Several compounds potently inhibited GCN2 in vitro and displayed good selectivity over the related kinases PERK, HRI, and IRE1. The compounds inhibited phosporylation of eIF2α in HEK293T cells with an IC50 < 150 nM, validating them as chemical probes for cellular studies. These probes were screened against the National Cancer Institute NCI-60 human cancer cell line panel. Uniform growth inhibition was observed in the leukemia group of cell lines. Growth inhibition in the most sensitive cell lines coincided with high GCN2 mRNA expression levels. Oncomine analysis revealed high GCN2 expression accompanied by lower asparagine synthetase (ASNS) expression in patient-derived acute lymphoblastic leukemias with B-Cell origins (B-ALL) as well. Notably, asparaginase, which depletes amino acids and triggers GCN2 activity, is a licensed, first-line B-ALL treatment. Thus, we hypothesize that leukemias exhibiting high GCN2 expression and low ASNS expression may be susceptible to pharmacologic GCN2 inhibition.
- 7 September 2016
- Published by Wiley in WIREs Mechanisms of Disease
- Vol. 8 (6) , 472-484
Data sources for in vivo molecular profiling of human phenotypes
Molecular profiling of human diseases has been approached at the genetic (DNA), expression (RNA), and proteomic (protein) levels. An important goal of these efforts is to map observed molecular patterns to specific, mechanistic organic entities, such as loci in the genome, individual RNA molecules or defined proteins or protein assemblies. Importantly, such maps have been historically approached in the more intuitive context of a theoretical individual cell, but diseases are better described in reality using an in vivo framework, namely a library of several tissue-specific maps. In this article, we review the existing data atlases that can be used for this purpose and identify critical gaps that could move the field forward from cellular to in vivo dimensions. WIREs Syst Biol Med 2016, 8:472–484. doi: 10.1002/wsbm.1354 This article is categorized under: Biological Mechanisms > Chemical Biology Laboratory Methods and Technologies > Genetic/Genomic Methods Laboratory Methods and Technologies > Proteomics Methods
- 7 September 2016
- Published by Wiley in WIREs Mechanisms of Disease
- Vol. 8 (6) , 472-484
Data sources for in vivo molecular profiling of human phenotypes
Molecular profiling of human diseases has been approached at the genetic (DNA), expression (RNA), and proteomic (protein) levels. An important goal of these efforts is to map observed molecular patterns to specific, mechanistic organic entities, such as loci in the genome, individual RNA molecules or defined proteins or protein assemblies. Importantly, such maps have been historically approached in the more intuitive context of a theoretical individual cell, but diseases are better described in reality using an in vivo framework, namely a library of several tissue-specific maps. In this article, we review the existing data atlases that can be used for this purpose and identify critical gaps that could move the field forward from cellular to in vivo dimensions. WIREs Syst Biol Med 2016, 8:472–484. doi: 10.1002/wsbm.1354 This article is categorized under: Biological Mechanisms > Chemical Biology Laboratory Methods and Technologies > Genetic/Genomic Methods Laboratory Methods and Technologies > Proteomics Methods
- Open Access
- 1 June 2016
- Published by Elsevier in Cell Reports
- Vol. 15 (10) , 2170-2184
Telomere Replication Stress Induced by POT1 Inactivation Accelerates Tumorigenesis
- 1 June 2016
- Published by Elsevier in Cell Reports
- Vol. 15 (10) , 2170-2184
Open AccessTelomere Replication Stress Induced by POT1 Inactivation Accelerates Tumorigenesis